3-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)imidazo[1,2-b]pyridazine
• 化学式: C₂₃H₂₀N₄O₃
• 分子量: 400.437
• InChiKey: RIVLTPBZTWPJLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS
  申请人：CALIFIA BIO, INC.

  公开号：US20160228437A1

  公开（公告）日：2016-08-11

  Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.

  本文提供了具有对混合谱系激酶（MLKs）具有抑制作用的咪唑吡啶化合物，它们的合成方法以及治疗方法。还提供了包括这些化合物的药物组合物和使用这些化合物和药物组合物的方法。
• [EN] HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2022108849A1

  公开（公告）日：2022-05-27

  The invention relates to compounds of structural formula I wherein A is independently N or C-R3, R1is selected from (C1to C6) alkyl, (C2to C6) alkenyl, (C2to C6) alkynyl, (C3to C10) cycloalkyl, (C5to C10) cycloalkenyl, (C2to C9) heterocycloalkyl, (C6to C10) aryl, and (C2to C9) heteroaryl, wherein each of the said (C1to C6) alkyl, (C2to C6) alkenyl, (C2to C6) alkynyl, (C3to C10) cycloalkyl, (C5to C10) cycloalkenyl, (C2to C9) heterocycloalkyl, (C6to C10) aryl, and (C2to C9) heteroaryl is optionally substituted with at least one R4group, and wherein said (C2to C9) heteroaryl is C-attached, and R2is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V) and formula (VI)..

  本发明涉及结构式I的化合物，其中A独立地为N或C-R3，R1选择自(C1到C6)烷基，(C2到C6)烯基，(C2到C6)炔基，(C3到C10)环烷基，(C5到C10)环烯基，(C2到C9)杂环烷基，(C6到C10)芳基，和(C2到C9)杂芳基，其中所述的(C1到C6)烷基，(C2到C6)烯基，(C2到C6)炔基，(C3到C10)环烷基，(C5到C10)环烯基，(C2到C9)杂环烷基，(C6到C10)芳基，和(C2到C9)杂芳基中的每一个都可以选择性地用至少一个R4基团取代，并且所述的(C2到C9)杂芳基是连接在碳上的，R2选择自公式(II)，公式(III)，公式(IV)，公式(V)和公式(VI)的群。
• US20140256733A1
  申请人：——

  公开号：US20140256733A1

  公开（公告）日：2014-09-11
• Heterocyclic Compounds for the Treatment of Arenavirus
  申请人：Arisan Therapeutics Inc.

  公开号：US20190308938A1

  公开（公告）日：2019-10-10

  The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R 3 , G, H, and J are independently N or C, K is N or C—H, L is N, N—R 3 or C—R 3 , and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R 1 is selected from (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and 5-indolyl, wherein each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is substituted with at least one R 4a group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached, and R 2 is selected from the group consisting of
• US9370515B2
  申请人：——

  公开号：US9370515B2

  公开（公告）日：2016-06-21